Figure 1.
Angiotensin II type 1 receptor blockers (ARBs) improve vascular remodelling and metabolic syndrome associated with anti-atherogenic effects, and reduce atrial fibrillation, resulting in reduction of onset of stroke. AF, atrial fibrillation; DM, diabetes mellitus; TIA, transient cerebral ischaemic attack.